

Prostate cancer at a glance

Prostate cancer is a very common diagnosis, in fact it's estimated to be the second most common cancer diagnosis in American men.¹



268,490
estimated new
cases, 2022



34,500
estimated
deaths, 2022



1 in 8
men will
be diagnosed

Risk factors

A risk factor is anything that could increase the likelihood of getting cancer

Race/Ethnicity: African American and Caribbean men of African ancestry are at higher risk²

Family history: Men with first degree relatives that have a history of prostate, breast, ovarian, or pancreatic cancers

Genetic changes: Men with inherited gene mutations in *BRCA1*, *BRCA2*, or Lynch Syndrome genes²

Screening

Early detection offers the greatest chance of living cancer free or reduced treatment.



PSA test: A blood test that can raise suspicion of cancer



Digital rectal exam: Feeling the prostate for hard, lumpy or abnormal areas



Prostate biopsy: Examining removed prostate tissue for cancer

Genetic testing for prostate cancer can help you understand the following:

- How aggressive your prostate cancer is
- If you are a candidate for active surveillance or if you should pursue active treatment - like surgery or radiation
- Your risk of cancer spreading outside of the prostate
- Are you a candidate for new, life-sustaining therapies

Learn more about prostate
cancer screening



Learn more about genetic
testing in prostate cancer



¹<https://www.cancer.org/cancer/prostate-cancer/about/key-statistics.html>

²<https://www.cancer.org/cancer/prostate-cancer/causes-risks-prevention/risk-factors.html>


Myriad Genetics offers genetic testing options to better understand your individual cancer risk and customize your treatment journey

Prolaris®

Prostate Cancer Prognostic Test

Tumor testing for untreated men with prostate cancer

Myriad Genetics' Prolaris Prostate Cancer Prognostic Test looks at your unique cancer and determines how aggressive your tumor is, giving you confidence to choose the right treatment, determines your risk of dying from the disease and the probability of the cancer spreading.



- 1 Men with prostate cancer that is not considered to be aggressive, may be safely monitored using active surveillance
- 2 Men with more aggressive tumors should consider one form of treatment
- 3 Men with very aggressive cancer could benefit from two or more forms of treatment

Myriad's genetic testing offers benefits for you and your family

Regardless of where you are in your prostate cancer journey, genetic testing can help you create a more customized treatment plan.

Benefits for individuals:

- Qualify for targeted therapies, if cancer spreads outside the prostate
- Identify risk of developing additional cancers
- Impact early treatment decision making

Benefits for families:

- Increased surveillance and screening
- Preventative surgery and medication to reduce risk
- Prevent future cancers

BRACAnalysis CDx®

Germline Companion Diagnostic Test

A diagnostic test that can determine if you qualify for new FDA approved targeted therapies; therapies that can maintain your quality of life and give you more time. By identifying if you have a germline BRCA 1/2 mutation, the test quickly and accurately establishes whether you're an appropriate candidate for PARP inhibitor therapy.

MyRisk™

Hereditary Cancer Test

The Myriad MyRisk test is a multi-gene cancer panel that will provide you with comprehensive information about your unique cancer. Using industry-leading accuracy, unmatched turnaround time, and a lifetime commitment to patients, MyRisk is an essential part of prostate cancer evaluation.

Why Myriad germline testing?



Myriad. Health. Illuminated.



The Myriad Genetics advantage

- 5 million patients tested
- Committed to keeping your genetic privacy safe
- Lifetime commitments to helping you understand your results and disease
- Recommended by national cancer organizations and treatment guidelines
- Committed to making testing easy and affordable

Is genetic testing affordable?

Most people have insurance that covers Myriad products and the exact amount you owe can vary based on your plan or your individual financial situation.



Medicare covers at 100%



Financial aid available



>93% of patients pay \$0

If you would like help getting started with genetic testing or have additional questions, visit Prolaris.com or contact a Myriad specialist below:

Email: UrologyTestSupport@myriad.com

Phone: 513-216-4752



Myriad Genetics, Inc.
320 Wakara Way
Salt Lake City, UT
84108

Prolaris.com

Myriad, the Myriad logo, Prolaris, the Prolaris logo, BRACAnalysis CDx, the BRACAnalysis CDx logo, MyRisk and the MyRisk logo are either trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and other jurisdictions.

©2022, Myriad Genetic Laboratories, Inc.